4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Astrocytoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 1024 ongoing clinical trials involving Astrocytoma
Of the 1024 trials,299 trials are in Phase II
Furthermore, 251 trials are in Phase I/II

Number of ongoing Clinical Trials (for drugs) involving Astrocytoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Astrocytoma, a Respiratory condition. The highest number of ongoing clinical trials involving Astrocytoma is in North America. Asia-Pacific and Europe are among some of the other prominent regions involved in Astrocytoma-related drug trials.

National Cancer Institute US: The leading ongoing Astrocytoma-related clinical trials sponsor

National Cancer Institute US, the US-based government institute, is the top sponsor for Astrocytoma-related ongoing clinical trials.

University of Texas MD Anderson Cancer Center, University of California San Francisco, Dana-Farber/Harvard Cancer Center, Dana-Farber Cancer Institute Inc, and Sidney Kimmel Comprehensive Cancer Center are a few other notable sponsors involving Astrocytoma.

A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Astrocytoma

Bevacizumab (Avastin), Everolimus (Afinitor, Votubia, RAD001), and Bevacizumab biosimilar (Mvasi) are among the key marketed drugs involving Astrocytoma.

Bevacizumab (Avastin) is a recombinant humanized monoclonal IgG1 antibody. It functions via the Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA) Inhibitor. It is formulated as an injection for intravenous administration. Avastin in combination with xeloda or paclitaxel is indicated for the treatment of metastatic breast cancer. In combination with cisplatin (or carboplatin) and etoposide, bevacizumab is indicated for the treatment of small-cell lung cancer. Avastin is used for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer (with carboplatin and paclitaxel for first-line treatment of unresectable, locally advanced, recurrent, or metastatic disease), and glioblastoma, with interferon alfa. Bevacizumab was first approved in 2004 and is marketed globally including the US, the UK, France, Germany, China, and Japan by several prominent pharma giants including Genentech USA Inc.

Everolimus (Afinitor, Votubia, RAD001) is an ester of the macrocytic immunosuppressive agent and acts as an anti-neoplastic agent. It functions via Serine/Threonine Protein Kinase mTOR Inhibitor. Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist mechanism of action. It is formulated as tablets for oral administration. Afinitor is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole, adults with progressive neuroendocrine tumors of pancreatic origin (PNET), and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic, adults with advanced renal cell carcinoma (RCC) after the failure of treatment with sunitinib or sorafenib. Everolimus was first approved in 2009 and is marketed globally including the US, the UK, France, Germany, and Japan by Novartis AG and its subsidiaries.